Does high-resolution donor typing of HLA-C or other loci upon registration confer advantages to patients?

Hum Immunol. 2011 Nov;72(11):1033-8. doi: 10.1016/j.humimm.2011.08.007. Epub 2011 Aug 10.

Abstract

Our study compared all requests for confirmatory typing (CT requests) received in our center between May 2007 and December 2009 (n = 134) for donors issued from 3 groups defined by different human leukocyte antigen (HLA) loci typed at different levels of resolution. We observed a significant advantage for volunteers when HLA-C 2-digit typing was available or with HLA-A, -B, -C, -DRB1 4-digit typing compared with generic HLA-A, -B, -DRB1, -DQB1 DNA typing: increased percentage of CT requests (p < 0.001), increased rate of donor selection for donation (p < 0.001), and decreased time frame for donor search (p = 0.025). The time frame for a successful search (donation) is similar among the 3 groups, indicating that the search might be concluded more rapidly when the pathology is clinically active or when the patient is at a high risk of relapse (76% of our cases) or for pediatric patients (24% of our cases), regardless of HLA typing resolution. Improvement of HLA typing for volunteers could be a great advantage for first selection in the absence of emergency or high-risk disease. Knowledge of HLA-C should be used to prioritize the selection of donors for further testing and could allow a better donor selection process, reducing search duration and increasing efficiency. In most cases, 2-digit typing for HLA-C associated with specific tools to estimate the probability of finding a matched donor could be sufficient.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Marrow Transplantation*
  • Child
  • Disease Progression
  • Donor Selection* / methods
  • Donor Selection* / standards
  • France
  • HLA-C Antigens / genetics*
  • Haplotypes
  • Histocompatibility / genetics
  • Histocompatibility / immunology
  • Histocompatibility Testing / methods
  • Histocompatibility Testing / standards
  • Humans
  • Linkage Disequilibrium
  • Registries*
  • Sensitivity and Specificity
  • Treatment Outcome

Substances

  • HLA-C Antigens